Document
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase IIIb ATTUNE study - http://orbis.uaslp.mx/vivo/individual/scopus3124
rights: termsOfUse
date: 2026-08-24T21:51:20
publisher: vivo
type: Document

Article
type: Class

Annals of the Rheumatic Diseases
type: Collection
type: Thing
type: Continuant
type: Periodical
type: Generically Dependent Continuant
publication venue for: Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase IIIb ATTUNE study
type: Journal
type: Document
type: Entity
type: Information Content Entity

Information Content Entity
type: Class

Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase IIIb ATTUNE study
type: Article
origen: scopus
pmid: 22302417
related by: authorship_18191
abstract: Objective: To assess safety, immunogenicity and efficacy in rheumatoid arthritis (RA) patients switched from longterm intravenous to subcutaneous (SC) abatacept. Methods: In this phase IIIb, open-label, single-arm trial, patients who completed ≥4 years of intravenous abatacept (in long-term extensions of two phase III studies) were enrolled to receive SC abatacept (125 mg/week). The primary objective was safety during the first 3 months after switching from intravenous therapy. Results: 123 patients entered the study (mean Disease Activity Score 28 (based on C reactive protein) and HAQ-DI of 3.4 and 0.94, respectively). At month 3, 120 (97.6%25) patients were continuing to receive SC abatacept; no patients discontinued due to lack of efficacy. Adverse events (AEs) were reported in 49 (39.8%25) patients through month 3. One patient (0.8%25) discontinued due to an AE and one patient (0.8%25) experienced a serious AE. Two (1.6%25) patients had SC injection site reactions (erythema, pain), both with mild intensity. Clinical efficacy was maintained throughout. Limited impact on immunogenicity was observed when switching routes of administration. Conclusion: These data demonstrate that patients can switch from long-term monthly intravenous abatacept to a weekly fixed dose of 125 mg SC abatacept with no increased safety concerns. This study further supports SC abatacept as an alternative treatment option for patients with RA.
related by: authorship_18192
related by: authorship_18201
e iscopus: 2-s2.0-84860916327
related by: authorship_18199
type: Document
related by: authorship_18193
type: Thing
estado: published
type: Continuant
related by: authorship_18194
issue: 6
related by: authorship_18190
has publication venue: Annals of the Rheumatic Diseases
related by: authorship_18200
related by: authorship_18197
most specific type: Article
doi: 10.1136/annrheumdis-2011-200355
related by: authorship_18198
type: Entity
volume: 71
date time value: article date 3125
freetext keyword: abatacept; C reactive protein; corticosteroid; disease modifying antirheumatic drug; methotrexate; nonsteroid antiinflammatory agent; tumor necrosis factor inhibitor; article; brain tumor; breast cancer; bronchitis; drug efficacy; drug fatality; drug safety; drug withdrawal; erythema nodosum; gastroenteritis; human; immunogenicity; injection site erythema; injection site pain; major clinical study; musculoskeletal pain; open study; phase 3 clinical trial; pneumonia; priority journal; rheumatoid arthritis; rhinopharyngitis; sarcoidosis; sinusitis; treatment outcome; upper respiratory tract infection; urinary tract infection; uterus cancer; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunoconjugates; Injections, Intravenous; Injections, Subcutaneous; Joints; T-Lymphocytes; Time; Treatment Outcome
type: Information Content Entity
related by: authorship_18195
page end: 861
type: Generically Dependent Continuant
crisid: 3125
related by: authorship_18196
chemicalscas: C reactive protein, 9007-41-4; abatacept, 332348-12-6; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; C-Reactive Protein, 9007-41-4; Immunoconjugates; abatacept
page start: 857
most specific type: Document